Drug Profile
Research programme: protein folding modulators - Biogen
Alternative Names: Protein folding modulators - Biogen; Protein misfolding reagents for neurodegenerative diseases - Biogen; RTA 801; SOD1 reactivators - Biogen; SOD1 stabilisers - BiogenLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Reata Pharmaceuticals
- Developer Biogen
- Class Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Protein folding modulators; Superoxide dismutase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease
Most Recent Events
- 26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (PO)